The ease of use and reproducibility of the alere™ heart check system: A comparison of patient and healthcare professional measurement of BNP

Biomarkers in Medicine

Volumn 8, Issue 6, 2014, Pages 791-796

  Lang, Ninian N ^a   Wong, Chih M ^a   Dalzell, Jonathan R ^a   Jansz, Sandra ^a   Leslie, Stephen J ^b   Gardner, Roy S ^a  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b RAIGMORE HOSPITAL   (United Kingdom)

Author keywords

BNP; heart failure; home monitoring

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CARDIOVASCULAR MONITORING DEVICE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; HEALTH CARE PERSONNEL; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; POINT OF CARE TESTING; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; REPRODUCIBILITY; AGED; BLOOD; CLINICAL TRIAL; FEMALE; HOSPITAL INFORMATION SYSTEM; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTPATIENT DEPARTMENT;

AGED; AMBULATORY CARE FACILITIES; FEMALE; HEALTH PERSONNEL; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS;

EID: 84907262638     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.48     Document Type: Article

References (20)

1. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 332(6159), 78-81 (1988).
2. Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 94(1), 40-43 (2008).
3. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am. J. Respir. Crit. Care Med. 178(4), 425-430 (2008).
4. Lainchbury JG, Troughton RW, Strangman KM et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol. 55(1), 53-60 (2009).
5. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49(16), 1733-1739 (2007).
6. Maisel A, Barnard D, Jaski B et al. Primary results of the HABIT Trial (heart failure assessment with BNP in the home). J. Am. Coll. Cardiol. 61(16), 1726-1735 (2013).
7. Berger R, Moertl D, Peter S et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J. Am. Coll. Cardiol. 55(7), 645-653 (2010).
8. Alere NHS health checks (2013). www.alere.co.uk/nhs-health-checks/aleretm-heart-check-312/product-listing.htm
9. Goonewardena SN, Blair JE, Manuchehry A et al. Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. J. Card. Fail. 16(1), 69-75 (2010).
10. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347(3), 161-167 (2002).
11. Gardner RS, Chong KS, McDonagh TA. B-type natriuretic peptides in heart failure. Biomark. Med. 1(2), 243-250 (2007).
12. Hulsmann M, Berger R, Sturm B et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur. Heart J. 23(11), 886-891 (2002).
13. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105(20), 2392-2397 (2002).
14. Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J. Am. Coll. Cardiol. 37(7), 1781-1787 (2001).
15. Gardner RS, Chong KS, Morton JJ, McDonagh TA. A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. Eur. J. Heart Fail. 9(3), 266-271 (2007).
16. Banner NR, Bonser RS, Clark AL et al. UK guidelines for referral and assessment of adults for heart transplantation. Heart 97(18), 1520-1527 (2011).
17. Zile MR, Bennett TD, St John SM et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 118(14), 1433-1441 (2008).
18. Ritzema J, Troughton R, Melton I et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 121(9), 1086-1095 (2010).
19. Ky B, French B, McCloskey K et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail. 4(2), 180-187 (2011).
20. van der Velde AR, Gullestad L, Ueland T et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ. Heart Fail. 6(2), 219-226 (2013).